Novartis Ag

Other

Irm LLC

Novartis Pharma Gmbh

Osamu Ohmori

Ichiro Umemura

Naoko Matsuura

Eiji Kawahara

Takahiro Miyake

Keiichi Masuya

Hidetomo Imase

Carlos Garcia-Echeverria

Takanori Kanazawa

Rudolf Duthaler

Gebhard Thoma

Yuki Iwaki

Nigel Graham Cooke

Gerhard Zenke

Klaus Hinterding

Anette Von Matt

Rolf Baenteli

Masashi Kishida

Kazuhiko Nonomura

Christos Papageorgiou

Toshiyuki Honda

Nathanael Schiander Gray

Donald Karanewsky

Muneto Mogi

Qiong Zhang

Yongqin Wan

Qiang Ding

Toshio Kawanami

Ruo W Steensma

Kayo Yasoshima

Ken Yamada

Jiqing Jiang

Greg Chopiuk

Hongbo Qin

The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP. 

Organic compounds

There are provided compounds of formula I wherein X, R, R, R, R, R, R, R, Rand Rare as indicated in claim 1 , useful in disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades connected with FAK.

2,4-diaminopyrimidine derivatives

The present invention relates to novel compounds of formula (I) or a pharmaceutical composition thereof, with all the variables being defined in the text. The present invention further relates to the use of the compounds herein for treatment of or delay progression to overt to diseases in which CETP is involved.

Bicyclic derivatives as CETP inhibitors

Novel pyrimidine derivatives of formula I to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

Pyrimidine derivatives

Novel pyrimidine derivatives of formula I to process for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

There are provided compounds of formula I wherein X, R, R, R, R, R, R, R, Rand Rare as indicated in claim, useful in disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades connected with FAK.

2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

Growing community of inventors

Tsukuba, Japan

Osamu Ohmori